SCPS News and Press, Scopus BioPharma Inc.

DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus B...

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”) , a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is...

Nasdaq said Wednesday it will delist shares of Waitr ( OTCQB:ASAP ), Calithera Biosciences ( OTC:CALA ), Statera Biopharma ( OTCPK:STAB ), Allied Healthcare Products ( OTC:AHPI ) and Tricida ( OTCPK:TCDAQ ). The exchange will also delist Eqonex ( OTCPK:EQOSQ ), Sco...

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet Bi...

Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet Duet Being Position...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! Penny stocks rule this morning’s movers with many rising and fa...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for another dive into the biggest pre-market stock movers as we see why shares are moving Thursday morning! Moving stocks this morning is clinical trial data, propo...

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology NEW YORK, March 22, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a cli...

Overwhelming Majority of Shares Voted by Unaffiliated Stockholders were in Favor of Scopus' Director Nominees Lasters’ Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual Meeting Will Depend o...

DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORS Former CEO/Director Dr. Morris C. Laster Believes Election of New Directors to Scopus's Board Will Help Ensure Effective, Independent Oversight of Company's Aff...